New Zealand markets close in 3 hours 20 minutes
  • NZX 50

    -103.31 (-0.82%)

    -0.0011 (-0.18%)

    -0.0008 (-0.14%)

    -77.30 (-0.94%)
  • ASX 200

    -70.80 (-0.89%)
  • OIL

    -0.33 (-0.43%)
  • GOLD

    -28.50 (-1.18%)

    -721.91 (-3.65%)
  • FTSE

    -13.68 (-0.17%)
  • Dow Jones

    -504.23 (-1.25%)
  • DAX

    -170.24 (-0.92%)
  • Hang Seng

    -50.22 (-0.29%)
  • NIKKEI 225

    -1,534.87 (-3.88%)

    -0.6550 (-0.72%)

Paragon 28 Inc (FNA) Q1 2024 Earnings: Aligns with Revenue Projections and Reaffirms Full-Year ...

  • Revenue: Reported $61.08 million, up 17.4% year-over-year, surpassing the estimated $60.10 million.

  • Net Loss: Reported a net loss of $15.23 million, deepening from a net loss of $9.05 million year-over-year, and above the estimated net loss of $11.11 million.

  • Earnings Per Share: Reported a loss of $0.18 per share, falling short of the estimated loss of $0.13 per share.

  • Operating Expenses: Increased to $61.80 million from $50.87 million in the previous year, reflecting higher costs in selling, general, and administrative expenses.

  • 2024 Revenue Guidance: Reaffirmed, projecting net revenue between $249 million and $259 million, indicating a growth rate of 15.1% to 19.7% compared to 2023.

  • Adjusted EBITDA: Reported a negative $5.48 million, compared to a negative $1.42 million in the prior year, indicating increased operational challenges.

  • International Revenue Growth: Reported a significant increase of 42.2% year-over-year, showcasing strong growth in global markets.

On May 8, 2024, Paragon 28 Inc (NYSE:FNA), a prominent player in the orthopedic implant industry focusing on foot and ankle medical devices, disclosed its financial outcomes for the first quarter ended March 31, 2024. The details were released in their latest 8-K filing. The company not only provided a snapshot of its recent financial performance but also confirmed its revenue forecast for the year.

Company Overview

Based in Englewood, CO, Paragon 28 Inc specializes in developing, distributing, and marketing a comprehensive range of medical devices specifically designed for foot and ankle surgeries. The company's innovative product portfolio includes plates, screws, and other related systems, catering to various orthopedic needs such as fracture fixation and deformity correction. Predominantly, its operations and revenue generation are concentrated in the United States.

Q1 2024 Performance Highlights

Paragon 28 reported a net revenue of $61.08 million for the first quarter of 2024, marking a 17.4% increase from the $52.04 million recorded in the same period last year. This performance is in line with analyst expectations which projected revenues around $60.10 million. The company's gross profit saw a rise to $48.90 million compared to $43.13 million in Q1 2023, driven by higher sales and operational efficiencies.


Despite the revenue growth, the company faced challenges as reflected in its net loss of $15.23 million for the quarter, compared to a net loss of $9.05 million in the previous year. This increase in net loss was primarily due to higher operating expenses, which surged to $61.80 million from $50.87 million, underscoring significant investments in research and development as well as sales and administrative efforts to support growth.

Financial Position and Future Outlook

Paragon 28's reaffirmed revenue guidance for 2024 stands at $249 million to $259 million, anticipating a growth rate of 15.1% to 19.7% over 2023. This projection assumes stable foreign currency exchange rates. The company's balance sheet remains robust with $58.22 million in cash, although down from $75.64 million at the end of 2023. The decrease in cash reserves is attributed to intensified operational and investment activities aimed at fueling its strategic expansions.

Operational and Strategic Developments

Albert DaCosta, Chairman and CEO of Paragon 28, expressed optimism about the company's trajectory, citing increased surgeon engagement and expansion in commercial channels both domestically and internationally. The introduction of new products and a steadfast focus on innovation and educational initiatives in the foot and ankle segments are expected to bolster sustainable growth moving forward.

Investor and Analyst Perspectives

From an investment standpoint, while the increased net loss might concern some stakeholders, the consistent revenue growth and strategic positioning in the niche market of foot and ankle orthopedics could present long-term value. The company's efforts to expand its product offerings and penetrate new markets are pivotal in its strategy to enhance shareholder returns.

For detailed financial figures and further information, stakeholders and potential investors are encouraged to view the full earnings report and listen to the webcast of the earnings call available on Paragon 28's investor relations website.

As Paragon 28 continues to navigate through its growth phases, the alignment of its Q1 performance with market expectations and the reaffirmation of its full-year revenue outlook reflect a resilient operational stance amidst a competitive and dynamic market environment.

Explore the complete 8-K earnings release (here) from Paragon 28 Inc for further details.

This article first appeared on GuruFocus.